Life Tech Teams with SGC on Epigentic Antibodies | GenomeWeb

NEW YORK (GenomeWeb News) – Life Technologies has struck a collaborative partnership with the Structural Genomics Consortium to develop and release 200 highly specific epigenetic recombinant antibodies, the company said today.

The partners have now released 58 of these antibodies, a move that SGC Director and CEO Aled Edwards said in a statement marks "the first step toward developing the defacto standard set of quality epigenetics antibodies that researchers can use for generations to come."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.